3/20
06:20 pm
ocgn
Oppenheimer Initiates Ocugen (OCGN) With a Buy Rating [Yahoo! Finance]
Neutral
Report
Oppenheimer Initiates Ocugen (OCGN) With a Buy Rating [Yahoo! Finance]
3/20
10:12 am
ocgn
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development [Yahoo! Finance]
Low
Report
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development [Yahoo! Finance]
3/17
09:00 am
ocgn
Ocugen (OCGN) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $12.00 price target on the stock.
Low
Report
Ocugen (OCGN) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $12.00 price target on the stock.
3/14
03:37 am
ocgn
Why Ocugen (OCGN) Is Up 54.0% After OCU400 Phase 3 Progress And Going Concern Spotlight [Yahoo! Finance]
Medium
Report
Why Ocugen (OCGN) Is Up 54.0% After OCU400 Phase 3 Progress And Going Concern Spotlight [Yahoo! Finance]
3/12
01:36 pm
ocgn
How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story [Yahoo! Finance]
Low
Report
How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story [Yahoo! Finance]
3/11
11:46 am
ocgn
Ocugen spikes as Oppenheimer issues new Outperform on upcoming catalysts [Seeking Alpha]
Medium
Report
Ocugen spikes as Oppenheimer issues new Outperform on upcoming catalysts [Seeking Alpha]
3/11
10:43 am
ocgn
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline [Yahoo! Finance]
Low
Report
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline [Yahoo! Finance]
3/11
08:03 am
ocgn
Ocugen (OCGN) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $10.00 price target on the stock.
High
Report
Ocugen (OCGN) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $10.00 price target on the stock.
3/9
03:58 pm
ocgn
Ocugen: Downgrading After OCU410 Data Release [Seeking Alpha]
Neutral
Report
Ocugen: Downgrading After OCU410 Data Release [Seeking Alpha]
3/5
09:28 am
ocgn
Ocugen (OCGN) had its "buy" rating reaffirmed by Chardan Capital. They now have a $7.00 price target on the stock.
Medium
Report
Ocugen (OCGN) had its "buy" rating reaffirmed by Chardan Capital. They now have a $7.00 price target on the stock.
3/4
01:43 pm
ocgn
Ocugen outlines 2026 BLA submission and expects three pivotal filings within three years amid leadership expansion [Seeking Alpha]
Medium
Report
Ocugen outlines 2026 BLA submission and expects three pivotal filings within three years amid leadership expansion [Seeking Alpha]
3/4
01:43 pm
ocgn
Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/4
12:52 pm
ocgn
Ocugen, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Ocugen, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
3/4
10:57 am
ocgn
Ocugen Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Ocugen Q4 Earnings Call Highlights [Yahoo! Finance]
3/4
10:17 am
ocgn
Ocugen (OCGN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Ocugen (OCGN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/4
08:43 am
ocgn
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
High
Report
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
3/4
08:15 am
ocgn
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
3/2
07:35 am
ocgn
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa [Yahoo! Finance]
High
Report
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa [Yahoo! Finance]
3/2
07:02 am
ocgn
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
High
Report
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
2/18
07:30 am
ocgn
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
2/18
07:02 am
ocgn
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
2/11
08:37 pm
ocgn
What The Latest Developments Mean For Ocugen's Changing Valuation Story [Yahoo! Finance]
Low
Report
What The Latest Developments Mean For Ocugen's Changing Valuation Story [Yahoo! Finance]
2/11
07:42 am
ocgn
What's driving record CFO turnover? [Fortune]
Low
Report
What's driving record CFO turnover? [Fortune]
2/9
07:02 am
ocgn
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
Neutral
Report
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
1/23
08:00 am
ocgn
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
Low
Report
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock